SEC Form 4 · accession 0001179022-19-000026
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joel Lewis
Director
Period of report
Feb 7, 2019
Accepted (ET)
Feb 11, 2019 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 7, 2019 | P | 1,000 | $4.4841 | A | 65,133 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were purchased in multiple transactions at prices ranging from $4.48 to $4.4871. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.